Narciclasine inhibits vaccinia virus infection by activating the RhoA signaling pathway  

作　　者：Ting Xu Zhengyang Pan Xue Li Mengyang Zhao Zichen Li Leiliang Zhang 

机构地区：[1]Department of Clinical Laboratory Medicine,The First Affiliated Hospital of Shandong First Medical University&Shandong Provincial Qianfoshan Hospital,Jinan 250014,China [2]Department of Pathogen Biology,School of Clinical and Basic Medical Sciences,Shandong First Medical University&Shandong Academy of Medical Sciences,Jinan 250117,China

出　　处：《Biosafety and Health》2024年第6期341-349,共9页生物安全与健康(英文)

基　　金：supported by the National Natural Science Foundation of China(82272306 and 82072270);Shandong Provincial Natural Science Foundation(ZR2024MH017);Taishan Scholars Program(tstp20221142).

摘　　要：In 2022,a sharp rise in global cases of mpox virus(MPXV)led the World Health Organization(WHO)to declare it a public health emergency of international concern.However,progress in developing drugs targeting MPXV has been slow.Here,we investigate the natural alkaloid narciclasine as a potential inhibitor of poxviruses.Our investigation demonstrates that narciclasine at 40 nmol/L(nM)to 160 nM dosages effectively blocks vaccinia virus(VACV),a representative poxvirus.Specifically,narciclasine disrupts the production of extracellular enveloped virus(EEV),which is crucial for viral spread.Narciclasine’s antiviral impact is probably attributed to its activation of the RhoA signaling pathway.This study highlights narciclasine’s potential as a promising new therapeutic candidate against poxviruses,offering prospects for its development into a potent antiviral agent that is essential for combating emerging poxvirus outbreaks.

关 键 词：Mpox virus(MPXV) Vaccinia virus(VACA) NARCICLASINE RHOA Extracellular enveloped virus(EEV) 

分 类 号：R511[医药卫生—内科学]